𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Entecavir treatment for chronic hepatitis B infection in end-stage renal disease and kidney transplantation

✍ Scribed by Ezequiel Ridruejo; Raúl Adrover; Cristina Alonso; Oscar G. Mandó; Marcelo O. Silva

Publisher
Wiley (John Wiley & Sons)
Year
2010
Tongue
English
Weight
73 KB
Volume
39
Category
Article
ISSN
0090-2934

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Low HBV-DNA levels in end-stage renal di
Low HBV-DNA levels in end-stage renal disease patients with HBeAg-negative chronic hepatitis B
✍ Renata S. Moutinho; Renata M. Perez; José O. Medina-Pestana; Mauro S. Figueiredo 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 1 views

## Abstract In end‐stage renal disease patients treated by hemodialysis with HBeAg‐negative chronic hepatitis B virus (HBV) infection, the evaluation of the presence of viral replication is essential in the assessment for renal transplantation. Data on HBV viral load, prevalence of precore mutation

Protective antibody levels and dose requ
Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease
✍ Rolland C. Dickson; Norah A. Terrault; Michael Ishitani; K. Rajender Reddy; Patr 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 1 views

Lamivudine combined with Hepatitis B immune globulin (HBIg) prevents post liver transplant (LT) HBV recurrence. The study was designed to assess the impact of lamivudine on hepatitis B antibody (anti-HBs) and dosage requirements of intravenous 5% HBIg (Nabi-HB) in the first 36 weeks post LT. Adults